FGF2 and breast carcinoma: HA has the capacity to modulate the binding interactions of surface polyanions on membranes, as in breast cancer cells, the addition of LMW HA leads to the release of fibroblast growth factor 2 (FGF-2) from heparan sulfate proteoglycans, which in turn increases ECs migration and angiogenesis, independent of VEGF.